Fungal keratitis is a severe infection that often requires surgical intervention and is associated with poor outcomes. Penetrating keratoplasty allows for the complete removal of the fungal infiltrate and thus can be a turning point in therapy. The depth of pathogen invasion, which cannot always be reliably assessed by slit lamp examination, can be accurately determined through histological analysis of the corneal trephinate. In this study, we histologically analyzed two corneal trephinates obtained during an emergency keratoplasty performed for uncontrollable mycotic infections. In case 1, caused by Candida albicans, the infiltrate remained localized at the site of pathogen entry. In contrast, in case 2, Fusarium falciforme demonstrated extensive tissue invasion, spreading destructively throughout the cornea. This invasion pattern suggests that Fusarium keratitis is difficult to control due to its aggressive spreading behavior within the tissue. This explains the high rate of penetrating keratoplasty required in such cases.
Perioperative immune-checkpoint inhibition (ICI) using pembrolizumab (3 doses of pembrolizumab 200 mg every 3 weeks before surgery and 15 doses afterwards) in advanced resectable melanoma has shown substantial pathological response rates and improved event-free survival (EFS) compared to postoperative (adjuvant) ICI. Real-world evidence on efficacy and safety of perioperative ICI in melanoma remains limited. In this retrospective single-centre study, 20 patients with resectable stage IIIB–IV melanoma were treated with perioperative pembrolizumab. Radiological and pathological responses, early survival outcomes and treatment-related adverse events were analysed at a median follow-up of 13.9 months. Eighteen patients (18/20) underwent surgery. A pathological complete response was observed in 44% (8/18), while 56% (10/18) showed a pathological non-response. No patient (0/18) had a pathological partial response. One-year EFS was 66.5% (95% confidence interval (CI) 47.3–93.3), 1-year relapse-free survival 77.6% (95% CI 57.9–100) and 1-year overall survival 89.2% (95% CI 76.0–100, identical with 1-year melanoma-specific survival). Immune-related adverse events occurred in 50% of the patients (≥grade 3 in 15%). Our study confirms the feasibility of perioperative pembrolizumab in a real-world setting and shows promising efficacy and tolerability in melanoma. Pathological response may guide surgical and adjuvant strategies.
Aim: To evaluate the efficacy of somatostatin receptor (SSTR)-directed PET/CT in localizing phosphaturic mesenchymal tumors (PMT) in patients with suspected tumor-induced osteomalacia (TIO) and to explore relationships between imaging parameters and biochemical markers. Methods: This retrospective analysis included 20 patients with suspected TIO, undergoing SSTR-directed PET/CT. Imaging findings and laboratory markers were assessed. SSTR-positive tumors were resected, while patients without detectable tumor, but persistent renal phosphate wasting, continued on medical treatment. Follow-up assessments included laboratory values and clinical examinations. Results: PMT were detected on PET in 12 patients (60%), were resected, and confirmed immunohistochemically. Phosphorus levels ( r = 0.26; p = 0.03), tubular reabsorption of phosphate (TRP; r = 0.77; p < 0.01) and tubular maximum of phosphate reabsorption over GFR (TmP/GFR; r = 0.44; p = 0.07) were lower in patients with detected PMT compared to those without. Elevation of fibroblast growth factor 23 (FGF23) was not significantly higher in PMT positive vs negative patients (253% vs 134% above the upper limit of normal; p = 0.97). Total lesion uptake (TLU) negatively correlated with TmP/GFR ( r = -0.71; p = 0.03). A maximum standardized uptake value (SUVmax) threshold of 7.6 differentiated PMT from bone fractures (83% sensitivity; 100% specificity). Post-resection follow-up confirmed clinical cure in all cases. Conclusion: In SSTR-directed PET/CT, a distinction between PMT and bone fracture may be possible with a SUVmax threshold of 7.6. The integration of PET derived TLU, along with TmP/GFR may improve diagnosis and treatment planning for TIO.